🦊/Investors

Advent Life SciencesFull Portfolio

90 tracked investments · listed companies and verified rows first

Agenusagenusbio.comNASDAQ: AGEN

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in

Co-investorsGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalCommodore CapitalInvusLigand Pharmaceuticals+1 more

Aura Biosciencesaurabiosciences.comin𝕏NASDAQ: AURA

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsChiesi VenturesDroia VenturesForesite CapitalJazzya InvestmentsMedicxiMyelin VC+4 more

Emergent Biosolutionsemergentbiosolutions.comin𝕏NYSE: EBSOct 2018

Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.

Advanced ManufacturingBiotechHealthtechGaithersburg, US

Fuad El-Hibri(Director, Executive Officer)inRobert G Kramer(Executive Officer)inKatherine Strei(Executive Officer)Adam R Havey(Executive Officer)inDaniel J Abdun-Nabi(Executive Officer, Director)inJoseph C. Papa(President, CEO and Director)

Co-investorsOrbiMed

Shionogishionogi.comOTC: SGIOF

Shionogi is a pharmaceutical company that discovers and develops medicines for challenging human diseases, including antibiotics and treatments for HIV, influenza, and COVID-19.

BiotechHealthtech

Co-investorsSolas BioVentures

Beacontxbeacontx.comin𝕏✓ verified

Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

BiotechDigital HealthMedical Devices

Daniel Chung(Chief Medical Officer)inLance Baldo(Chief Executive Officer)inAbraham Scaria(Chief Scientific Officer)in

Co-investorsForbionOxford Science EnterprisesTCG Crossover

Orphalanorphalan.comin✓ verified

Orphalan develops and commercializes innovative therapies for patients with rare diseases, with a focus on unmet medical needs where current treatments are limited or absent.

BiotechHealthtechImpact & Social GoodMedical DevicesParis, FR

Massimo BorieroinDmitry ParamonovinJohn FatuhiSandra BensoussaninAngelita BriffainOmar Camille Kamlin

Co-investorsBpifrance

Relief Cardiovascularreliefcardio.com✓ verified

Relief Cardiovascular develops transcatheter smart implant systems for volume management in congestive heart failure, including the Relief System, a preload-modulating implant for inferior vena cava flow modulation with autonomous hemodynamic monitoring.

BiotechHealthtechMedical DevicesCosta Mesa, US

Co-investorsBroadview VenturesGood Growth CapitalVensana Capital

Tridek-One’s websitetridekone.comin✓ verified

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.

BiotechDeep TechHealthtechParis, FR

Co-investorsBioqube VenturesBpifrancePureos BioventuresAdBio partners

visit www.levicept.comlevicept.com✓ verified

Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.

BiotechHealthtechMedical Devices

Simon Westbrook(Founder and CSO)

Co-investorsGilde HealthcareIndex VenturesMedicxiPfizer VenturesPfizer Venture Investments

Arrakis Therapeuticsarrakistx.comin𝕏Feb 2017

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)

BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in

Board seatRaj ParekhAlan Walts· per SEC Form D

Co-investorsCanaan PartnersPfizer VenturesNextech InvestOUP (Osage University Partners)Pfizer Venture InvestmentsvenBio Partners+1 more

Artax Biopharmaartaxbiopharma.comin𝕏May 2026

Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.

BiotechHealthtechCambridge, US

Damia Tormo(President, CEO, Treasurer and Founder)inJoe Suarez(Executive Officer)Maria Nichol(Executive Officer)inRobert W. Armstrong, Ph.D.(Executive Officer, Director)Rob Armstrong(CEO)in

BoardAndre Hoekema(Director)

Board seatRaj ParekhAlan Walts· per SEC Form D

Co-investorsSound BioventuresColumbus Venture Partners

Genocea BiosciencesinFeb 2019SEC filingmedium confidence

Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.

BiotechCambridge, US

Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)inMichael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)

Board seatKatrine Bosley· per SEC Form D · $15M raise · filed Feb 2019

Co-investorsCycad Group LLCLux CapitalMC Healthcare VenturesAlexandriaAuriga PartnersBill & Melinda Gates Foundation+1 more

Macrolide PharmaceuticalsinMar 2018

BiotechWatertown, US

Edward Mascioli(Executive Officer)Andrew Myers(Director)

BoardMarkus Goebel(Director)Henry Skinner(Director)inVikas Goyal(Director)

Board seatRaj Parekh· per SEC Form D

Co-investorsGurnet Point CapitalNovartis Venture FundRoche Venture Fund

Moximedmoximed.comSeries C · Aug 2024 · $50M

HealthtechFremont, US

Anton Clifford(Executive Officer)inJames Leech(Executive Officer)inChristopher Gleason(Executive Officer)inKevin K. Sidow(Executive Officer, Director)

BoardJoshua Makower(Director)

Board seatShahzad Malik· per SEC Form D

Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalGBS Venture Partners Ltd.Gilde HealthcareVertex Ventures HC

Acutus Medicalacutusmedical.comSeries A · Sep 2011 · $5M

HealthtechCarlsbad, US

Christoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVince Burgess(Director)inJohn Dahldorf(Executive Officer)

BoardAditya Puri(Director)

Co-investorsOrbiMedDeerfield Management CompanyFormation GroupGE VenturesIndex Ventures

AlphaRose Therapeuticsalpharose.comin

AlphaRose develops genetic technologies and treatments for children with rare genetic diseases, aiming to make and commercialize such medicines at scale.

BiotechHealthtech

Amphistaamphista.comin𝕏Series A · Apr 2020 · $7.5M

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in

Co-investorsNovartis Venture FundSV Health InvestorsDementia Discovery FundEuropean Investment FundForbionGilde Healthcare+2 more

Aravivearavive.comOct 2022

BiotechHouston, US

Amato Giaccia(Director)Rudy Howard(Chief Financial Officer)Robert B. Geller(Chief Medical Officer)inGail McIntyre(Chief Executive Officer)Leonard Scott Dove(Chief Operating Officer)Joshua Brumm(Executive Officer)

Co-investors3E Bioventures CapitalEshelman Ventures, LLC

Argá Medtechargamedtech.comFeb 2024

Argá Medtech is developing a non-thermal cardiac ablation system based on a proprietary Pulsed Field Ablation (PFA) technology using sine wave energy and a proprietary catheter to treat atrial fibrillation and other heart arrhythmias.

HardwareHealthtechMedical Devices

Co-investorsEarlybird Venture CapitalGilde Healthcare

Aspire Ftdaspire-ftd.com

AviadoBio is a biotech company focused on frontotemporal dementia (FTD), a form of early-onset dementia.

BiotechHealthtechMedical Devices

David Cooper(Chief Medical Officer)Farah Speer(SVP, Communications and External Relations)

AviadoBio Websiteaviadobio.comin𝕏

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

BiotechDeep TechDigital HealthHealthtech

Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)inDo Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)inLisa Deschamps(Chief Executive Officer)inGraeme Fielder(Chief Operating Officer)inAlex Bloom(Chief Development Officer)in

Co-investorsDementia DiscoveryF-Prime CapitalLifeArc VenturesMonograph Capital PartnersNew Enterprise Associates (NEA)

Axonicsaxonics.comin

Boston Scientific develops medical devices and technologies used by healthcare professionals to treat patients across a range of conditions.

HealthtechMedical Devices

Raymond Cohenin

Co-investorsAndera PartnersLongitude Capital

Biocartisbiocartis.comin𝕏

Biocartis develops molecular diagnostic testing systems for cancer, with a focus on enabling personalized medicine through rapid, in-house biomarker analysis.

BiotechDigital HealthHealthtechMedical DevicesMechelen, BE

Co-investorsKorysNew Rhein Healthcare Investors, LLCPMV

Cdccdc.govin𝕏

The CDC Foundation is a nonprofit authorized by Congress that mobilizes philanthropic and private-sector resources to support the Centers for Disease Control and Prevention's public health mission.

Digital HealthGovTechHealthtechImpact & Social GoodAtlanta, US

Centessa Pharmaceuticalscentessa.com

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsEcoR1 CapitalForesite CapitalMedicxiOberland CapitalScion Life SciencesVida Ventures+1 more

Cytedcytedhealth.comSeries B · Aug 2025 · $44M

Cyted Health develops diagnostics for earlier and more accurate detection of esophageal disease, including its EndoSign capsule sponge cell collection device and molecular diagnostics, intended for clinicians screening for conditions such as Barrett's Esophagus and esophageal cancer.

BiotechHealthtechMedical Devices

Epitopeaepitopea.cominSeed · Oct 2024 · $31M

Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.

AI & Machine LearningBiotechHealthtechMontreal, CA

Claude PerreaultPierre Thibault

Co-investorsCambridge Innovation CapitalCTI Life Sciences Fund L.P.adMare BioInnovationsFonds de solidarité FTQ

F2Gf2g.com

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSofinnova PartnersSunstone Capital+3 more

Glycomine www.glycomine.comglycomine.comin𝕏

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.

Biotech

Steven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in

Co-investorsMission Bay CapitalMission BiocapitalRemiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures

Iterum Therapeuticsiterumtx.comSeries B · May 2017 · $65M

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

Michael W. Dunne(Executive Officer, Promoter)inCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)

BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)

Co-investorsBay City CapitalCanaan PartnersSofinnova VenturesFrazier Life SciencesSofinnova Venture Partners

Little Dog Communications Inc.litldog.comin𝕏

Little Dog Communications is a biotech communications firm that helps life science companies translate complex scientific and technical concepts into clear narratives for investors, media, and other stakeholders.

BiotechMarketing TechSan Diego, US

Jessica Yingling(Ph.D., President)

Nalunalumed.comin𝕏Jun 2015

Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.

HardwareHealthtechMedical DevicesCarlsbad, US

Earl Fender(President & CEO)inLee Hartley(Executive Officer)inAllen Meacham(Executive Officer)inBick Sellers(Executive Officer)inThomas A. West(Executive Officer, Director)inJeffrey Swiecki(Executive Officer)

Co-investorsAPERTURE Venture PartnersB Capital GroupB4 CapitalDecheng CapitalEndeavour VisionLongitude Capital+1 more

NCT05101187clinicaltrials.gov

ClinicalTrials.gov is a public registry and results database of clinical studies conducted around the world, maintained by the U.S.

Digital HealthHealthtech

Co-investorsYsios Capital

Nerre Therapeuticsnerretherapeutics.comSeries B · Jan 2017 · $29M

Co-investorsFountain Healthcare PartnersOrbiMedColumbus Venture PartnersForbionRedwood Ventures

Pheno Therapeutics Websitephenotherapeutics.comin

Pheno Therapeutics is a clinical-stage biotech company developing GPR17 antagonists that target oligodendrocytes to promote brain repair.

BiotechMedical DevicesEdinburgh, GB

Neil Carragher(Founder)in

Co-investorsLifeArc Ventures

Pic Therapeuticspictherapeutics.comSeed · Apr 2020 · $5M

BiotechBoston, US

Dr. Richard Peters(Director)Belinda Termeer(Director)Dr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)Sun Altbach(Executive Officer, Director)in

Co-investorsLumira VenturesOrbiMed

Proximieproximie.comin𝕏Series C · Apr 2022 · $80M

Proximie provides a cloud-based operating system for connected operating rooms, giving medtech companies and hospitals real-time OR connectivity, structured surgical data, and AI-driven insights.

AI & Machine LearningDigital HealthMedical DevicesSaaSAltrincham

Nadine Haram(Director)inNadine Hachach-Haram(Founder)inJonathan Lim(Director)inScott Huennekens(Director)in

BoardMohammed Shahzad Ahmed Malik(Director)

Co-investorsCapria VenturesCedar Mundi VenturesCOTU VenturesDraper AssociatesF-Prime CapitalQuesta Capital+5 more

Purespringpurespringtx.comin𝕏Series A · Nov 2020 · $60M

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.

BiotechDigital HealthHealthtechMedical Devices

Moin Saleem(Co-founder & Chief Scientific Advisor)in

Co-investorsSofinnova PartnersForbionGilde HealthcareBritish Patient Capital

Rapptarappta-therapeutics.comOct 2020

Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsNovartis Venture FundNovo Holdings

Uniqureuniqure.comin𝕏

uniQure is a biotech company developing gene therapies for serious genetic diseases.

BiotechHealthtechMedical Devices

Matthew Kapustain

Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERS

Versartisversartis.comSeries B · Feb 2011 · $21M

Co-investorsAisling CapitalSofinnova Ventures

Zyme Communicationszymecommunications.comin𝕏

Zyme Communications provides PR and marketing services to life science companies across Europe and the USA, helping them build visibility with investors, commercial partners, and customers through specialized communications and media outreach.

BiotechMarketing TechSaaS

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

AcutusALETAAlgetaArtaxAuraAvananAvilaAxonics Modular TechnologiesBeaconBeacon TherapeuticsCardiacAssistCardiAQCardiAQ Valve TechnologiesCardiokineCellnovoCn CreativeConatusCurveEloxxEmergentEUSAEUSA PharmaFdaGlycomineHighlightInfinityInfinity PharmaceuticalsIterumKandyKandy TherapeuticsKuDosLeviceptMicrometMiroBioNeRRePhenoPheno TherapeuticsPICPowderMedRespivertSantarusSEPThiakisTridek-OneVentusVentus MedicalVestagen Technical TextilesWondr Medical

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.